Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Change in Acquisitions & Divestments (2019 - 2025)

Historic Change in Acquisitions & Divestments for Pliant Therapeutics (PLRX) over the last 7 years, with Q3 2025 value amounting to $80.3 million.

  • Pliant Therapeutics' Change in Acquisitions & Divestments fell 2622.95% to $80.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $323.8 million, marking a year-over-year decrease of 1302.89%. This contributed to the annual value of $355.5 million for FY2024, which is 2221.22% down from last year.
  • Pliant Therapeutics' Change in Acquisitions & Divestments amounted to $80.3 million in Q3 2025, which was down 2622.95% from $87.2 million recorded in Q2 2025.
  • Over the past 5 years, Pliant Therapeutics' Change in Acquisitions & Divestments peaked at $152.8 million during Q3 2023, and registered a low of $33.8 million during Q3 2022.
  • Its 5-year average for Change in Acquisitions & Divestments is $80.9 million, with a median of $78.2 million in 2021.
  • As far as peak fluctuations go, Pliant Therapeutics' Change in Acquisitions & Divestments plummeted by 5536.16% in 2022, and later soared by 35216.58% in 2023.
  • Pliant Therapeutics' Change in Acquisitions & Divestments (Quarter) stood at $64.3 million in 2021, then dropped by 12.12% to $56.5 million in 2022, then surged by 58.36% to $89.5 million in 2023, then decreased by 18.76% to $72.7 million in 2024, then grew by 10.5% to $80.3 million in 2025.
  • Its last three reported values are $80.3 million in Q3 2025, $87.2 million for Q2 2025, and $83.5 million during Q1 2025.